Atlas Trials

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Clinical trial NCT05832892 · UNKNOWN

Trial details

NCT number
NCT05832892
Sponsor
Shanghai Zhongshan Hospital
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Start date
2023-11-01
Primary completion
2024-11-01
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.